Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Stage of Development | 8 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Therapy Area | 9 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Indication | 10 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Companies | 13 | 2 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Companies Involved in Therapeutics Development | 21 | 6 |
| Alteogen Inc. | 21 | 1 |
| Chengdu Kanghong Pharmaceuticals Group Co Ltd | 22 | 1 |
| Clearside BioMedical, Inc. | 23 | 1 |
| Formycon AG | 24 | 1 |
| Regeneron Pharmaceuticals Inc | 25 | 1 |
| ThromboGenics NV | 26 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drug Profiles | 27 | 32 |
| (aflibercept + nesvacumab) Drug Profile | 27 | 1 |
| (aflibercept + rinucumab) Drug Profile | 28 | 2 |
| (aflibercept + triamcinolone acetonide) Drug Profile | 30 | 3 |
| aflibercept Drug Profile | 33 | 12 |
| aflibercept biosimilar Drug Profile | 45 | 1 |
| aflibercept biosimilar Drug Profile | 46 | 1 |
| conbercept Drug Profile | 47 | 2 |
| SL-186 Drug Profile | 49 | 1 |
| SL-188 Drug Profile | 50 | 1 |
| TG-931 Drug Profile | 51 | 1 |
| THR-317 Drug Profile | 52 | 3 |
| ziv-aflibercept Drug Profile | 55 | 4 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Dormant Projects | 59 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Discontinued Products | 60 | 1 |
| Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Featured News &Press Releases | 61 | 12 |
| Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting | 61 | 1 |
| Sep 30, 2016: Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration | 61 | 1 |
| Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS | 62 | 1 |
| Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion | 63 | 1 |
| Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance | 64 | 1 |
| May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection | 65 | 1 |
| May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma | 65 | 1 |
| Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | 66 | 1 |
| Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 | 67 | 1 |
| Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven | 68 | 1 |
| Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept) | 68 | 1 |
| Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 | 69 | 1 |
| Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration | 70 | 1 |
| Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization | 70 | 1 |
| Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication | 71 | 2 |
| Appendix | 73 | 2 |
| Methodology | 73 | 1 |
| Coverage | 73 | 1 |
| Secondary Research | 73 | 1 |
| Primary Research | 73 | 1 |
| Expert Panel Validation | 73 | 1 |
| Contact Us | 73 | 1 |
| Disclaimer | 74 | 1 |